Clinical Trial Update: Insulin Glargine for Diabetes Metabolism(DM)Type II Patients Under Enteral Nutrition [Phase 4]

View source ↗

Summary

A Phase 4 trial evaluating insulin glargine for type 2 diabetes patients receiving enteral nutrition was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• Lantus (insulin glargine)

Snippet

Sponsor: Sanofi | Conditions: Diabetes Mellitus, Type 2 | Phase 4 | Status: TERMINATED